The strategic Central Nervous System Therapeutics Market forecast predicts a strong expansion, anticipating the market value to reach USD 360.29 billion by 2035, up from USD 178.89 billion in 2024. This growth reflects a robust Compound Annual Growth Rate (CAGR) of 6.57% during the forecast period (2025–2035), emphasizing the sector's long-term potential for investors and pharmaceutical developers.

Key to this optimistic Central Nervous System Therapeutics Market forecast is the acceleration of personalized medicine approaches. Genetic profiling and advanced diagnostics are enabling researchers to stratify patient populations, allowing for the development and approval of highly targeted therapies, such as the recent full FDA approval of certain monoclonal antibodies for early Alzheimer's disease. These breakthroughs for previously intractable conditions are expected to significantly boost market revenues and reshape treatment paradigms.